Compare LQDA & LMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | LMND |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.2B |
| IPO Year | 2020 | 2020 |
| Metric | LQDA | LMND |
|---|---|---|
| Price | $47.98 | $39.74 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 11 |
| Target Price | $54.38 | ★ $56.33 |
| AVG Volume (30 Days) | ★ 3.9M | 1.2M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | 21.40 |
| EPS | ★ 1.26 | N/A |
| Revenue | $158,320,000.00 | ★ $737,900,000.00 |
| Revenue This Year | $357.27 | $67.61 |
| Revenue Next Year | $1.34 | $34.93 |
| P/E Ratio | $35.40 | ★ N/A |
| Revenue Growth | ★ 1031.18 | 40.15 |
| 52 Week Low | $22.31 | $39.11 |
| 52 Week High | $93.61 | $99.90 |
| Indicator | LQDA | LMND |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 37.46 |
| Support Level | $35.00 | N/A |
| Resistance Level | $63.46 | $47.31 |
| Average True Range (ATR) | 3.10 | 2.42 |
| MACD | 1.61 | -0.32 |
| Stochastic Oscillator | 77.29 | 16.14 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.